Trial Profile
A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Tamoxifen
- Indications Breast cancer; Ductal carcinoma
- Focus Biomarker; Pharmacodynamics
- 23 Jun 2009 Planned initiation date (Jan 2007), actual end date (Jun 2008) and planned number of patients (100) added as reported by ClinicalTrials.gov.
- 23 Jun 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 22 Jan 2008 The expected completion date for this trial is now 1 Jan 2009.